SCHEMBL7607277

SCHEMBL7607277

O[C@H]1CCCC[C@@H]1n1c(Br)nc2cc(Cl)c(Cl)cc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 2/20 0.50
CDK9 P50750 2/20 0.50
PRPS1 P60891 4/20 0.39
HDAC6 Q9UBN7 1/20 0.35
SLC15A1 P46059 1/20 0.33
JAK2 O60674 1/20 0.32
JAK1 P23458 1/20 0.32
SLC18A3 Q16572 1/20 0.32
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
ALDH1A1 P00352 1/20 0.31
GLA P06280 1/20 0.31
POLB P06746 1/20 0.31
GAA P10253 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
RAB9A P51151 1/20 0.31
KMT2A Q03164 1/20 0.31
CYP11B1 P15538 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7607284 1.00 CCNT1 (0.50) CCNT1CDK9PRPS1HDAC6SLC15A1
SCHEMBL7607282 1.00 CCNT1 (0.50) CCNT1CDK9PRPS1HDAC6SLC15A1
SCHEMBL7643447 0.89 CCNT1 (0.45) CCNT1CDK9PRPS1HDAC6SLC15A1
SCHEMBL7611059 0.89 CCNT1 (0.45) CCNT1CDK9PRPS1HDAC6SLC15A1
SCHEMBL7611063 0.89 CCNT1 (0.45) CCNT1CDK9PRPS1HDAC6SLC15A1
SCHEMBL8658052 0.84 CCNT1 (0.43) CCNT1CDK9PRPS1HDAC6SLC15A1
SCHEMBL8658051 0.84 CCNT1 (0.43) CCNT1CDK9PRPS1HDAC6SLC15A1
SCHEMBL7608537 0.80 CCNT1 (0.45) CCNT1CDK9HDAC6SLC15A1SLC18A3
SCHEMBL7608534 0.80 CCNT1 (0.45) CCNT1CDK9HDAC6SLC15A1SLC18A3
SCHEMBL7608539 0.80 CCNT1 (0.45) CCNT1CDK9HDAC6SLC15A1SLC18A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6455507-B1 E.G., 2-BROMO-5,6-DICHLORO-1-BETA-D-RIBOPYRANOSYL-1H-BENZIMIDAZOLE; VIRICIDES, ESPECIALLY INFECTIONS OF HERPES AND CYTOMEGALO VIRUSES SMITHKLINE BEECHAM CORPORATION 2002-09-24 US claimed
EP-0994890-A2 BENZIMIDAZOLE DERIVATIVES GLAXO GROUP LIMITED (GB) 2000-04-26 EP claimed
WO-1998056761-A2 BENZIMIDAZOLE DERIVATIVES GLAXO GROUP LIMITED (GB) 1998-12-17 WO claimed
US-6455507-B1 E.G., 2-BROMO-5,6-DICHLORO-1-BETA-D-RIBOPYRANOSYL-1H-BENZIMIDAZOLE; VIRICIDES, ESPECIALLY INFECTIONS OF HERPES AND CYTOMEGALO VIRUSES SMITHKLINE BEECHAM CORPORATION 2002-09-24 US disclosed
US-20020094963-A1 BENZIMIDAZOLE DERIVATIVES GLAXO WELLCOME INC. 2002-07-18 US disclosed
EP-0994890-A2 BENZIMIDAZOLE DERIVATIVES GLAXO GROUP LIMITED (GB) 2000-04-26 EP disclosed
WO-1998056761-A2 BENZIMIDAZOLE DERIVATIVES GLAXO GROUP LIMITED (GB) 1998-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020094963-A1 BENZIMIDAZOLE DERIVATIVES ZC3HAV1, BRPF3, BRD3 CCNT1 483/4885CDK9 138/4885PRPS1 1137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.